Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX 4291 in Adults With Obesity
NCT07142707Phase 1Recruiting
- Sponsor
- MBX Biosciences, Inc.
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MBX 4291 in obesity (4 arms), sponsored by MBX Biosciences, Inc. Primary endpoint: Treatment Emergent Adverse Events at 148 days. Started Sep 2025; status: recruiting.
02
Drugs
MBX 4291
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07142707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142707.